The long and short of the filing is this: Acad submitted an application under Rule 24b-2 requesting confidential treatment for info it excluded from the exhibits to a Form 10-Q filed on August 5,2009. Based on representations by ACAD that this info qualifies as confidential commercial or financial info under the Freedom of Information Act(sounds like Dick Cheeney) so the Division of Corporation Finance has determined not to publicly disclose it. The following exhibit(s) WILL NOT BE RELEASED to the public for the time period(s) as specfied. EXHIBIT 10.1......through MAY 1, 2014 and EXHIBIT 10.2........through APRIL 22, 2019. approved Brigitte Lippmann..Special Counsel. This was done because of the next filing on or near Monday 09, 2009....3rd QTR earnings. It is not too hard to figure out.....do your homework. dtl/solana partners. PS...if you have the time read about a firm called EPIX Pharma. Just Google 24b-2 and read about ACADIA and a firm called EPIX. Thanks very much. so you have a hint 5 and 10 years out. Good Luck.